The regulatory and research present
BPC-157 is a 15-amino-acid synthetic peptide with a three-decade preclinical record across tendon, gut, nerve, and cardiac tissue. As of mid-2026 it has no FDA approval and no IND on file, and the July 2026 PCAC hearing that took it up has no published vote record. This site summarizes the literature and the regulatory present — one panel at a time.
The short version
BPC-157 is a synthetic 15-amino-acid peptide first studied for its ability to protect the stomach lining. Thirty years of animal research have since shown it influences healing in tendons, ligaments, muscle, bone, gut, spinal cord, and cardiac tissue — all through a common mechanism involving the growth of new blood vessels (called angiogenesis) and a nitric oxide signaling cascade.
As of mid-2026, BPC-157 has no FDA approval, no approved human dose, and is prohibited in competitive sport by WADA. Only three small, uncontrolled human studies exist. The compound was on the agenda when the FDA's compounding advisory committee met in July 2026, and FDA has published no record of the committee's votes.
This site covers both panels: the preclinical research record and the regulatory present. For what research-use communities say about the experience of using it, see the effects page.
What is BPC-157?
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide with the sequence GEPPPGKPADDAGLV and a molecular weight of 1,419.54 Da. It was derived from a protein isolated from human gastric juice — not extracted from it — and is produced today by solid-phase peptide synthesis (SPPS). The compound also carries several research designations: PL 14736, PLD-116, and stable gastric pentadecapeptide BPC 157 [16].
The gastric origin matters mechanistically. BPC-157 is unusually stable in gastric juice for more than 24 hours — a property that distinguishes it from most peptides, which would be cleaved rapidly by stomach acid, and that is central to the compound's demonstrated oral activity in preclinical models [20].
Research-grade BPC-157 is typically supplied as a lyophilized acetate salt, specified at ≥98% purity by reverse-phase HPLC with ESI-MS identity confirmation. The compound exists in two salt forms — free base and acetate — and both have appeared in the regulatory literature. The FDA's July 2026 PCAC meeting listed both forms separately as candidates for potential inclusion on the 503A Bulks List.
The name 'Body Protection Compound' predates any clinical designation. It was assigned during early gastroprotection studies, when the peptide's cytoprotective effects on the gastric mucosa were its defining property [21]. Subsequent decades of research expanded the picture considerably.
What does three decades of preclinical research show?
The BPC-157 literature is substantial, largely concentrated in rodent models, and weighted heavily toward a single Croatian research group (Sikiric, Seiwerth, and collaborators at the University of Zagreb). Both the breadth and the concentration are worth noting plainly.
In musculoskeletal models, BPC-157 at 10 μg/kg intraperitoneal significantly improved Achilles tendon healing biomechanics — load-to-failure, stiffness, and Young's elasticity modulus — in rats with Achilles detachment. The same study showed the compound counteracted methylprednisolone-associated healing impairment [1]. A separate model of transected Achilles tendon confirmed accelerated healing and dose-dependent improvements in tendocyte growth in vitro [2].
In gastrointestinal models, BPC-157 at 400–800 ng/kg intramuscular reduced gastric ulcer area by 45–65% across three ulcer models in rats, outperforming famotidine at equivalent doses [8]. Colonic ischemia studies showed the peptide restored blood supply and mucosal folds within 15 minutes of topical application at 10 μg/kg [7].
Neural and cardiac findings extend the picture further. At 10 μg/kg intraperitoneal, administered 10 minutes post-injury, BPC-157 produced clinical improvement and motor function recovery through 360 days of follow-up in rats with spinal cord compression [10]. In an isoprenaline-induced myocardial infarction model, 10 ng/kg and 10 μg/kg intraperitoneal reduced cardiac enzyme markers and preserved left ventricular function [12].
A 2021 wound-healing review found that BPC-157 upregulated 19 wound-healing genes — including Akt1, Vegfa, Nos3, and several Mapk variants — within minutes to hours post-injury, and demonstrated efficacy across six distinct wound and injury model types in rats [15].
The consistent thread across all of these models is the same set of molecular targets: VEGFR2 upregulation, Akt-eNOS axis activation, and the downstream nitric oxide synthesis and angiogenesis that follows. A 2025 narrative review from McGuire and colleagues characterized this mechanism as the primary effector arm and noted no adverse effects across three published human studies [16].
What is the regulatory status as of mid-2026?
The regulatory present is active and unresolved. BPC-157 has no FDA approval for any human indication, no IND (Investigational New Drug) application on file in the United States, and no USP/NF monograph.
FDA placed BPC-157 on the 503A Category 2 list in September 2023; by the agency's April 22, 2026 page, it no longer appeared in Category 2 because the nomination had been withdrawn, though FDA has not explained how a compounding pharmacy should treat that change. TB-500 sits in the same withdrawn table, and FDA publishes no date for when either entry changed. Neither compound has been added to the 503A Bulks List, the final roster of permitted ingredients that FDA sets by rulemaking. That withdrawal left a regulatory gray zone: not explicitly prohibited, not authorized.
The FDA Pharmacy Compounding Advisory Committee (PCAC) had BPC-157 free base and BPC-157 acetate on its July 2026 agenda, with ulcerative colitis as the nominated use case. FDA staff had proposed against moving either form to the 503A Bulks List, and FDA has published no record of the committee's votes as of September 2026.
In parallel, WADA (the World Anti-Doping Agency) has prohibited BPC-157 under Section S0 — Non-Approved Substances — since 2022. Athletes in WADA-governed competition cannot use BPC-157 regardless of route or stated purpose.
For researchers: BPC-157 is classified as a research chemical and is not approved for human consumption by the FDA or any major regulatory agency.
What human data exists?
Three small published human studies exist as of 2025. Their findings are notable; their scale is not.
The most recent is a 2024 pilot study in 12 patients with moderate-to-severe interstitial cystitis (IC) who had failed pentosan polysulfate — the only FDA-approved IC therapy. Intravesicular BPC-157 injections produced 80–100% symptom resolution at six weeks in all 12 patients [18]. This is a striking outcome in a refractory population, and it represents the first published human data on intravesicular BPC-157.
Before that, a knee pain pilot study reported significant pain relief in 14 of 16 patients via intra-articular injection, and a two-subject IV safety study documented tolerance of up to 20 mg intravenous without adverse events [16].
A 2025 narrative review from McGuire and colleagues synthesized all three studies and concluded BPC-157 should be considered investigational pending controlled human trials — a characterization that is both accurate and deliberately cautious [16]. No randomized controlled trials have been published. A Phase 2 IBD trial (PL 14736, oral) was conducted by Pliva in Croatia but peer-reviewed results were never published — a gap that the clinical and regulatory literature frequently cites.
What this site is
BPC-157 Meds is a two-panel reading of the peer-reviewed literature on BPC-157 (Body Protection Compound 157): the studies on one side, the regulatory and compounding present on the other. It summarizes what has been published; it is not a service.
This site is not affiliated with any vendor, compounding pharmacy, or manufacturer. It does not provide medical advice and does not employ clinicians. The modifier 'meds' in the domain name is editorial framing — a statement about the regulatory context the compound currently occupies, not a service the site offers.
Every page here is commentary on the openly published science. Citations are drawn from PubMed, PMC, Frontiers in Pharmacology, and peer-reviewed journals. A complete reference list with DOIs and PubMed URLs is available on the References page.